Accelerate your preclinical drug development program

In Vivo Disease Models

With more than 150 validated animal models (rat and mouse), our catalog boasts wide therapeutic coverage from across 14 therapeutic areas. We also offer custom models, modifications to our existing models, and can even help you replicate models from the literature.

Explore our models or contact us for custom options.

Trusted by the Top Leaders in Pharmacology

Boehringer
AZLogo
Takeda
Biogen
Teva
Giled
Merck
Daiichi
JJ
Glaxo
Addex
Pfizer
LB

Phenotypic screening uncovers otherwise
unpredicted new uses for a drug

Our in vivo pharmacology contract research capabilities

In Vivo Services

We offer access to dozens of animal models of human disease. Our commitment to in vivo services since 2005 has made us a CRO of choice for hundreds of companies.

In Vivo Pharmacology Platforms

The theraTRACE® and opioidTRACE® platforms are our phenotypic screening tools for drug repositioning, drug repurposing, and indications discovery.

About Melior

More than just a provider of in vivo pharmacology services, Melior is a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning.

Its proprietary theraTRACE® platform enables rapid and
cost-effective identification of new therapeutic potential
by systematically screening candidates in a diverse array
of validated in vivo disease models.

Logo 1

Serving the pharma industry since 2005

Logo 2

Thousands of completed studies

Logo 3

Hundreds of compounds evaluated

Logo 4

Dozens of animal models of human disease

“Melior provided State-of-the-art Preclinical Pharmacology Support for a period of nearly a year where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly, and the operational processes were excellent. I can recommend Melior without reservation.”

Richard DiMarchi, PhD
Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences
Indiana University, Department of Chemistry

Recent Studies using Phenotypic Screening

Increasingly, phenotypic screening is being recognized as the best strategy to uncover otherwise unpredicted new uses of therapeutics.

Navigating from cellular phenotypic screen to clinical candidate: selective targeting of the NLRP3 inflammasome

Rosalie Matico, Karolien Grauwen, Dhruv Chauhan, Xiaodi Yu, Irini Abdiaj, Suraj Adhikary, Ine Adriaensen, Garcia Molina Aranzazu, Jesus Alcázar, Michela Bassi